Why TScan Therapeutics, Inc.’s (TCRX) Stock Is Down 8.95%
As of Tuesday, July 14, TScan Therapeutics, Inc.’s TCRX share price has dipped by 8.95%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Commentary & Analysis
Why TScan Therapeutics, Inc.’s (TCRX) Stock Is Down 15.08%
As of Thursday, July 09, TScan Therapeutics, Inc.’s TCRX share price has dipped by 15.08%, which has investors questioning if this is right time to buy.Jenna Brashear
Why TScan Therapeutics, Inc.’s (TCRX) Stock Is Down 12.30%
As of Thursday, July 09, TScan Therapeutics, Inc.’s TCRX share price has dipped by 12.30%, which has investors questioning if this is right time to buy.Michael Rose
Why TScan Therapeutics, Inc.’s (TCRX) Stock Is Up 5.61%
As of Wednesday, July 08, TScan Therapeutics, Inc.’s TCRX share price has surged by 5.61%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why TScan Therapeutics, Inc.’s (TCRX) Stock Is Up 10.18%
As of Wednesday, July 01, TScan Therapeutics, Inc.’s TCRX share price has surged by 10.18%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | TCRX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $52.6 | $286.3 | 16% |
|
| Shares Out (Mil) | 129.9 | 54.2 | 68% |
|
| Institutional Ownership | 99.6% | 92.8% | 91% |
|
| Float (Mil) | 57.8 | 39.7 | 50% |
|
| Beta | 1.07 | 0.94 | 65% |
|
| Avg Daily Volume (000s) | 360 | 534 | 53% |
|
| Price Change (52-week) |
(53.8%) | 58.7% | 13% |
|
| Growth | TCRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 56.4% | 13.6% | 97% |
|
| Net Income (5yr) | (37.8%) | (10.1%) | 10% |
|
| EPS (5yr) | 39.7% | 16.0% | 88 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 42.9% | (15.6%) | 91% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 4 | |
| Current EPS | ($0.218) | ($0.873) | ($0.935) | |
| Month Ago EPS | ($0.215) | ($0.843) | ($0.888) | |
| # Rev Up | 2 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.215) | ($0.843) | ($0.888) | |
| Year/Year Chg | (6.8%) | (61.7%) | (62.9%) | |
| Financials | TCRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $7 | $37 | 7% |
|
| Net Income (TTM) (Mil) | ($118) | ($43) | 10% |
|
| EPS (TTM) | ($1.737) | ($1.400) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | ($116) | ($31) | 5% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $72 | $4 | 42% |
|
| Enterprise Value (Q1) (Mil) | $44 | $160 | 15% |
|
| Valuation | TCRX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.76 | 2.77 | 14% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | TCRX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 64.2% | na |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (50.1%) | (47.3%) | 11% |
|
| ROE | (95.8%) | (55.0%) | 9% |
|
| Liabilities to Assets | 59.7% | 29.6% | 53% |
|
| F-Score | 3 | 2 | 18% |
|
TScan Therapeutics, Inc. did not pass any screens on 8/20/2026.
